Peter Schellongowski, Michael Darmon, Philipp Eller, Laveena Munshi, Tobias Liebregts, Victoria Metaxa, Luca Montini, Tobias Lahmer, Fabio S. Taccone, Andry van de Louw, Martin Balik, Peter Pickkers, Pleun Hemelaar, Hemang Yadav, Andreas Barratt-Due, Thomas Karvunidis, Jordi Riera, Gennaro Martucci, Ignacio Martin-Loeches, Pedro Castro, Nina Buchtele, Virginie Lemiale, Stefan Hatzl, Guillaume Dumas, Thomas Staudinger, Elie Azoulay
{"title":"癌症患者的急性呼吸窘迫综合征:YELENNA前瞻性多国观察队列研究","authors":"Peter Schellongowski, Michael Darmon, Philipp Eller, Laveena Munshi, Tobias Liebregts, Victoria Metaxa, Luca Montini, Tobias Lahmer, Fabio S. Taccone, Andry van de Louw, Martin Balik, Peter Pickkers, Pleun Hemelaar, Hemang Yadav, Andreas Barratt-Due, Thomas Karvunidis, Jordi Riera, Gennaro Martucci, Ignacio Martin-Loeches, Pedro Castro, Nina Buchtele, Virginie Lemiale, Stefan Hatzl, Guillaume Dumas, Thomas Staudinger, Elie Azoulay","doi":"10.1007/s00134-025-08113-7","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Acute respiratory failure is the leading reason for intensive care unit (ICU) admission among critically ill patients with cancer. We aimed to describe the clinical characteristics, risk factors, and outcomes of patients with cancer and acute respiratory distress syndrome (ARDS) and to evaluate associations of venovenous extracorporeal membrane oxygenation (ECMO) with outcomes in the subgroup with severe ARDS.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We conducted a multinational, prospective, observational cohort study of patients with cancer and ARDS in 13 countries in Europe and North America. The primary endpoint was 90-day mortality.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Among 715 included patients, 73.4% had hematologic malignancies and 26.6% solid tumors; 31.2% had undergone hematopoietic stem-cell transplantation (168 allogeneic). ICU, hospital, and 90-day mortality rates were 55.3%, 70.9%, and 73.2%, respectively. By multivariate analysis, independent predictors of higher 90-day mortality were older age, peripheral vascular disease, severe ARDS at inclusion, acute kidney injury, and ICU admission as a time-limited trial (vs. full code). Conversely, lymphoma was associated with lower 90-day mortality. Among the 322 patients (45.7%) with severe ARDS at inclusion, 90-day mortality was 82.2%; with no difference between patients who received ECMO (<i>n</i> = 58, 18%) and those who did not (82.6% vs. 80.7%, <i>P</i> = 0.89). This finding remained unchanged in a double-adjusted overlap- and propensity-weighted Cox mixed-effects model (adjusted hazard ratio, 1.12; 95% confidence interval 0.65–1.94; <i>P</i> = 0.69).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Patients with cancer and ARDS, particularly severe forms, experience high 90-day mortality, irrespective of ECMO use. These findings suggest a need for nuanced ICU goals-of-care discussions and raise concerns about the generalizability of ECMO guidelines to this population.</p>","PeriodicalId":13665,"journal":{"name":"Intensive Care Medicine","volume":"95 1","pages":""},"PeriodicalIF":21.2000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study\",\"authors\":\"Peter Schellongowski, Michael Darmon, Philipp Eller, Laveena Munshi, Tobias Liebregts, Victoria Metaxa, Luca Montini, Tobias Lahmer, Fabio S. Taccone, Andry van de Louw, Martin Balik, Peter Pickkers, Pleun Hemelaar, Hemang Yadav, Andreas Barratt-Due, Thomas Karvunidis, Jordi Riera, Gennaro Martucci, Ignacio Martin-Loeches, Pedro Castro, Nina Buchtele, Virginie Lemiale, Stefan Hatzl, Guillaume Dumas, Thomas Staudinger, Elie Azoulay\",\"doi\":\"10.1007/s00134-025-08113-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose</h3><p>Acute respiratory failure is the leading reason for intensive care unit (ICU) admission among critically ill patients with cancer. We aimed to describe the clinical characteristics, risk factors, and outcomes of patients with cancer and acute respiratory distress syndrome (ARDS) and to evaluate associations of venovenous extracorporeal membrane oxygenation (ECMO) with outcomes in the subgroup with severe ARDS.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>We conducted a multinational, prospective, observational cohort study of patients with cancer and ARDS in 13 countries in Europe and North America. The primary endpoint was 90-day mortality.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>Among 715 included patients, 73.4% had hematologic malignancies and 26.6% solid tumors; 31.2% had undergone hematopoietic stem-cell transplantation (168 allogeneic). ICU, hospital, and 90-day mortality rates were 55.3%, 70.9%, and 73.2%, respectively. By multivariate analysis, independent predictors of higher 90-day mortality were older age, peripheral vascular disease, severe ARDS at inclusion, acute kidney injury, and ICU admission as a time-limited trial (vs. full code). Conversely, lymphoma was associated with lower 90-day mortality. Among the 322 patients (45.7%) with severe ARDS at inclusion, 90-day mortality was 82.2%; with no difference between patients who received ECMO (<i>n</i> = 58, 18%) and those who did not (82.6% vs. 80.7%, <i>P</i> = 0.89). This finding remained unchanged in a double-adjusted overlap- and propensity-weighted Cox mixed-effects model (adjusted hazard ratio, 1.12; 95% confidence interval 0.65–1.94; <i>P</i> = 0.69).</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusion</h3><p>Patients with cancer and ARDS, particularly severe forms, experience high 90-day mortality, irrespective of ECMO use. These findings suggest a need for nuanced ICU goals-of-care discussions and raise concerns about the generalizability of ECMO guidelines to this population.</p>\",\"PeriodicalId\":13665,\"journal\":{\"name\":\"Intensive Care Medicine\",\"volume\":\"95 1\",\"pages\":\"\"},\"PeriodicalIF\":21.2000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Intensive Care Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00134-025-08113-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intensive Care Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00134-025-08113-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study
Purpose
Acute respiratory failure is the leading reason for intensive care unit (ICU) admission among critically ill patients with cancer. We aimed to describe the clinical characteristics, risk factors, and outcomes of patients with cancer and acute respiratory distress syndrome (ARDS) and to evaluate associations of venovenous extracorporeal membrane oxygenation (ECMO) with outcomes in the subgroup with severe ARDS.
Methods
We conducted a multinational, prospective, observational cohort study of patients with cancer and ARDS in 13 countries in Europe and North America. The primary endpoint was 90-day mortality.
Results
Among 715 included patients, 73.4% had hematologic malignancies and 26.6% solid tumors; 31.2% had undergone hematopoietic stem-cell transplantation (168 allogeneic). ICU, hospital, and 90-day mortality rates were 55.3%, 70.9%, and 73.2%, respectively. By multivariate analysis, independent predictors of higher 90-day mortality were older age, peripheral vascular disease, severe ARDS at inclusion, acute kidney injury, and ICU admission as a time-limited trial (vs. full code). Conversely, lymphoma was associated with lower 90-day mortality. Among the 322 patients (45.7%) with severe ARDS at inclusion, 90-day mortality was 82.2%; with no difference between patients who received ECMO (n = 58, 18%) and those who did not (82.6% vs. 80.7%, P = 0.89). This finding remained unchanged in a double-adjusted overlap- and propensity-weighted Cox mixed-effects model (adjusted hazard ratio, 1.12; 95% confidence interval 0.65–1.94; P = 0.69).
Conclusion
Patients with cancer and ARDS, particularly severe forms, experience high 90-day mortality, irrespective of ECMO use. These findings suggest a need for nuanced ICU goals-of-care discussions and raise concerns about the generalizability of ECMO guidelines to this population.
期刊介绍:
Intensive Care Medicine is the premier publication platform fostering the communication and exchange of cutting-edge research and ideas within the field of intensive care medicine on a comprehensive scale. Catering to professionals involved in intensive medical care, including intensivists, medical specialists, nurses, and other healthcare professionals, ICM stands as the official journal of The European Society of Intensive Care Medicine. ICM is dedicated to advancing the understanding and practice of intensive care medicine among professionals in Europe and beyond. The journal provides a robust platform for disseminating current research findings and innovative ideas in intensive care medicine. Content published in Intensive Care Medicine encompasses a wide range, including review articles, original research papers, letters, reviews, debates, and more.